Polycystic ovary syndrome (PCOS): diagnosis and metabolic screening
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Suspected PCOS: diagnosis and conditions to rule out
- Off combined oestrogen-progestogen contraception for at least 3 months; at the start of the follicular phase if cycles are preserved.
Laboratory tests (in the morning, before 8 am for 17-hydroxyprogesterone)
- Total testosterone (by mass spectrometry if possible)
- SHBG (to calculate the free androgen index)
- 17-hydroxyprogesterone (in the morning, at the start of the follicular phase)
- Serum prolactin
- TSH
- β-hCG (if amenorrhoea)if needednon-French guidelineAmenorrhoea (rather than oligomenorrhoea): exclude pregnancy [2].
- FSH and oestradiol (if amenorrhoea)if needednon-French guidelineAmenorrhoea: raised FSH and low oestradiol point to premature ovarian insufficiency; low or low-normal LH and FSH with low oestradiol point to hypothalamic amenorrhoea [2].
- Progesterone in the middle of the luteal phase (if cycles are regular, to confirm anovulation)if needednon-French guidelineHyperandrogenism with regular cycles, when the diagnosis depends on ovulatory dysfunction: the 2023 international guideline and its US synthesis propose measuring progesterone to confirm anovulation [1,3]. The sample is taken in the mid-luteal phase, on day 21 of a 28-day cycle [4].
- Delta-4-androstenedione (if testosterone normal)if needednon-French guidelineNormal total and free testosterone while hyperandrogenism is still suspected: can be measured, bearing in mind its lower specificity [1].
- DHEA-S (if testosterone normal, or suspected adrenal cause)if needednon-French guidelineNormal total and free testosterone: lower specificity and decline with age [1]; virilisation or rapid progression: very high levels in favour of a secreting tumour [2].
- AMH (adult, instead of ultrasound for ovarian morphology)if needednon-French guidelineAdult in whom only one of the other two criteria is present (irregular cycles or hyperandrogenism): AMH can replace ultrasound to define polycystic morphology; never alone, never together with ultrasound, not in adolescents [1].
- 24-hour urinary free cortisol (if signs of hypercortisolism)if needednon-French guidelineMany signs of hypercortisolism, especially the most discriminating ones (proximal muscle wasting, facial plethora, purple striae, easy bruising): screen for Cushing's syndrome with 24-hour urinary free cortisol, late-night salivary cortisol or the overnight dexamethasone suppression test [2].
Do not order
- AMH or ultrasound in adolescents: not recommended, for lack of specificity; the diagnosis then requires hyperandrogenism and cycle disorders [1].
- AMH when irregular cycles and hyperandrogenism are already present: pointless for diagnosis [1].
- Insulin, HOMA index or other measure of insulin resistance: imprecise measures, not recommended in clinical practice [1].
- Repeated androgens to follow adult PCOS: limited value [1].
Confirmed PCOS: initial cardiometabolic work-up
Fasting laboratory tests
- 75 g oral glucose tolerance test (fasting and 2-hour glucose)
- Lipid profile
- Fasting plasma glucose (if the OGTT is not possible)if needednon-French guidelineOGTT impossible or refused: fasting plasma glucose and/or HbA1c, markedly less accurate [1].
- HbA1c (if the OGTT is not possible)if needednon-French guidelineOGTT impossible or refused: alternative of lower accuracy [1,2].
Do not order
PCOS follow-up and pregnancy planning
Every 1 to 3 years depending on risk factors
- 75 g oral glucose tolerance test (or fasting plasma glucose if not possible)
- Lipid profile (depending on the presence of dyslipidaemia and cardiovascular risk)if needednon-French guidelineAfter the initial tests, the frequency of lipid tests depends on hyperlipidaemia and other risk factors or on overall cardiovascular risk [1].
Pregnancy plan or request for assisted reproduction
- 75 g oral glucose tolerance test
Also consider
Sources (9)
- Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al.; International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655-1679.
- Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.
- Nelson M, LaRouche V. Polycystic Ovary Syndrome: Assessment and Management Guidelines. Am Fam Physician. 2024;110(5):547-548.
- National Institute for Health and Care Excellence. Fertility problems: assessment and treatment. NICE guideline NG257, 31 mars 2026.
- Pugeat M, Déchaud H, Raverot V, Denuzière A, Cohen R, Boudou P; Société française d'endocrinologie. Recommendations for investigation of hyperandrogenism. Ann Endocrinol (Paris). 2010;71(1):2-7.
- Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0793 (AMH), 1577 (HbA1c), 1802 (SDHEA).
- Royal College of Obstetricians and Gynaecologists. Long-term Consequences of Polycystic Ovary Syndrome (Green-top Guideline No. 33). Page du guide, archivé le 13 décembre 2024.
- Williams T, Moore JB, Regehr J. Polycystic Ovary Syndrome: Common Questions and Answers. Am Fam Physician. 2023;107(3):264-272.